Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer

Breast Cancer

Volumn 20, Issue 2, 2013, Pages 145-151

  Kawano, Akiko ^a,b   Shimizu, Chikako ^a   Hashimoto, Kenji ^a   Kinoshita, Takayuki ^a   Tsuda, Hitoshi ^a   Fujii, Hirofumi ^b   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Clinical benefit; PgR; Prognostic factor; Second line endocrine therapy; Stage IV breast cancer

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GONADORELIN DERIVATIVE; LETROZOLE; MEDROXYPROGESTERONE; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST METASTASIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; DRUG RESISTANCE; FOLLOW UP; LUNG CARCINOMA; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84884805688     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-011-0320-3     Document Type: Article

References (22)

1. Muss HB, Case LD, Richards F 2nd, White DR, Cooper MR, Cruz JM, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med. 1991;325:1342-8.
2. Norton L. Metastatic breast cancer. Length and quality of life. N Engl J Med. 1991;325:1370-1.
3. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004;22:3302-8. (Pubitemid 41103686)
4. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100:44-52. (Pubitemid 37553538)
5. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer. 2003;97:545-53. (Pubitemid 36125831)
6. Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol. 2008;19:2012-9.
7. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
8. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-74. (Pubitemid 32878711)
9. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-23. (Pubitemid 36842560)
10. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339:974-84. (Pubitemid 28455101)
11. Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat. 1999;56:67-78. (Pubitemid 29435816)
12. Wilson AJ. Response in breast cancer to a second hormonal therapy. Rev Endocr Relat Cancer. 1983;14:5-11.
13. Von Roenn JH, Bonomi PD, Gale M, Anderson KM, Wolter JM, Economou SG. Sequential hormone therapy for advanced breast cancer. Semin Oncol. 1988;15:38-43.
14. Iveson TJ, Ahern J, Smith IE. Response to third-line endocrine treatment for advanced breast cancer. Eur J Cancer. 1993;29A:572-4. (Pubitemid 23036309)
15. Cheung KL, Willsher PC, Pinder SE, Ellis IO, Elston CW, Nicholson RI, et al. Predictors of response to second-line endocrine therapy for breast cancer. Breast Cancer Res Treat. 1997;45:219-24. (Pubitemid 27453790)
16. Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat. 2010;119:53-61.
17. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992;10:1284-91.
18. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808-16. (Pubitemid 32880059)
19. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol. 2005;23:7512-7. (Pubitemid 46291814)
20. Hu JC, Mokbel K. Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer? Eur J Surg Oncol. 2001;27:335-7. (Pubitemid 32624531)
21. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist. 2004;9(Suppl 3):20-6. (Pubitemid 38747836)
22. Eroles P, Bosch A, Bermejo B, Lluch A. Mechanisms of resistance to hormonal treatment in breast cancer. Clin Transl Oncol. 2010;12:246-52.